ValiRx PLC
LSE:VAL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
RFG Holdings Ltd
JSE:RFG
|
ZA |
|
CE Info Systems Ltd
NSE:MAPMYINDIA
|
IN |
|
A
|
Aeris Industria e Comercio de Equipamentos para Geracao de Energia SA
BOVESPA:AERI3
|
BR |
|
Amrutanjan Health Care Ltd
NSE:AMRUTANJAN
|
IN |
|
Riverside Resources Inc
XTSX:RRI
|
CA |
|
A
|
Avid Technology Inc
F:AVD
|
US |
|
Metalurgica Gerdau SA
BOVESPA:GOAU4
|
BR |
|
SVG Tech Group Co Ltd
SZSE:300331
|
CN |
|
Southstone Minerals Ltd
XTSX:SML
|
CA |
|
Hellofresh SE
XETRA:HFG
|
DE |
|
KIYO Learning Co Ltd
TSE:7353
|
JP |
|
Renewi PLC
LSE:RWI
|
UK |
|
Duckyang Industry Co Ltd
KRX:024900
|
KR |
|
Tameny Inc
TSE:6181
|
JP |
|
Melia Hotels International SA
MAD:MEL
|
ES |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
ValiRx PLC
LSE:VAL
|
2.3m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
384.5B USD |
Loading...
|
|
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
361.6B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
189.6B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.4B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.7B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
67.9B AUD |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -188 120% |
| 30th Percentile | 0% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 10 443.9% |
Other Profitability Ratios
ValiRx PLC
Glance View
ValiRx Plc is a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary and novel technology for precision medicines towards commercialization and partnering. The company is headquartered in Nuneaton, Warwickshire and currently employs 10 full-time employees. The company went IPO on 2000-02-28. The firm is engaged in the development of oncology therapeutics and companion diagnostics. The company focuses on the development of treatments in cancer and women’s health. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. Its VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer. Its VAL301 for the treatment of women with endometriosis. Its VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. Its BC201 is a combination of the peptide ingredient of VAL201 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. The company operates through divisional companies, including ValiPharma and ValiSeek.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for ValiRx PLC is -3 580.7%, which is above its 3-year median of -12 301.9%.
Over the last 1 years, ValiRx PLC’s Net Margin has increased from -21 226% to -3 580.7%. During this period, it reached a low of -21 226% on Dec 31, 2023 and a high of -3 580.7% on Jun 30, 2025.
